Integrated Filing — IndAS



General information about company

Scrip Code 500124
NSE Symbol DRREDDY
MSEI Symbol NOTLISTED
ISIN INE089A01031
Name of company Dr. Reddy's Laboratories Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 23-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-09-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 23-10-2026   15:00:00
End date and time of board meeting 23-10-2026   16:38:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 23-01-2025
Indicate Company website link for updated RPT policy of the Company https://drreddys.com/cms/sites/default/files/media-library//Policy%20on%20Materiality%20of%20Related%20Party%20Transactions%20and%20Dealing%20with%20Related%20Party%20Transactions%20%281%29.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
See accompanying notes to the financial results.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 5,57,260.00 10,70,920.00
Other income 21,730.00 65,770.00
Total income 5,78,990.00 11,36,690.00
2 Expenses
(a) Cost of materials consumed 1,28,420.00 2,58,980.00
(b) Purchases of stock-in-trade 72,260.00 1,62,480.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (720.00) (5,920.00)
(d) Employee benefit expense 95,740.00 1,92,440.00
(e) Finance costs 7,700.00 15,010.00
(f) Depreciation, depletion and amortisation expense 33,370.00 65,140.00
(f) Other Expenses
1 Impairment of non current assets (1,150.00) (1,000.00)
2 Other Expenses 1,53,240.00 3,09,730.00
Total other expenses 1,52,090.00 3,08,730.00
Total expenses 4,88,860.00 9,96,860.00
3 Total profit before exceptional items and tax 90,130.00 1,39,830.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 90,130.00 1,39,830.00
6 Tax expense
7 Current tax 19,690.00 24,700.00
8 Deferred tax 860.00 5,080.00
9 Total tax expenses 20,550.00 29,780.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 69,580.00 1,10,050.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 69,580.00 1,10,050.00
17 Other comprehensive income net of taxes (1,580.00) 8,340.00
18 Total Comprehensive Income for the period 68,000.00 1,18,390.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 8,350.00 8,350.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 8.35 13.21
Diluted earnings (loss) per share from continuing operations 8.35 13.2
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 8.35 13.21
Diluted earnings (loss) per share from continuing and discontinued operations 8.35 13.2
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) See accompanying notes to the financial results.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 8,07,570.00
Capital work-in-progress 1,12,270.00
Investment property 0.00
Goodwill 8,530.00
Other intangible assets 2,81,130.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 11,96,290.00
Trade receivables, non-current 0.00
Loans, non-current 30.00
Other non-current financial assets
1 Other financial assets 50,460.00
Total of other non-current financial assets 50,460.00
Total non-current financial assets 12,46,780.00
Deferred tax assets (net) 0.00
Other non-current assets
1 Tax assets, net 31,880.00
2 Other non-current assets 5,420.00
Total of other non-current assets 37,300.00
Total non-current assets 24,93,580.00
2 Current assets
Inventories 5,20,690.00
Current financial asset
Current investments 2,95,910.00
Trade receivables, current 4,99,070.00
Cash and cash equivalents 37,200.00
Bank balance other than cash and cash equivalents 2,22,730.00
Loans, current 15,380.00
Other current financial assets
Total of other current financial assets 95,270.00
Total current financial assets 11,65,560.00
Current tax assets (net)
Other current assets
1 Other current assets 2,57,200.00
Total of other current assets 2,57,200.00
Total current assets 19,43,450.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 44,37,030.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 8,350.00
Other equity 31,85,090.00
Total equity attributable to owners of parent 31,93,440.00
Non controlling interest
Total equity 31,93,440.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease liabilities 25,230.00
Total of other non-current financial liabilities 25,230.00
Total non-current financial liabilities 25,230.00
Provisions, non-current 1,200.00
Deferred tax liabilities (net) 66,870.00
Deferred government grants, Non-current
Other non-current liabilities
1 Other non-current liabilities 20,820.00
Total of other non-current liabilities 20,820.00
Total non-current liabilities 1,14,120.00
Current liabilities
Current financial liabilities
Borrowings, current 5,45,000.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 3,480.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,31,700.00
Total Trade payable 2,35,180.00
Other current financial liabilities
1 Lease liabilities 7,500.00
2 Derivative instruments 52,330.00
3 Other financial liabilities 2,04,580.00
Total of other current financial liabilities 2,64,410.00
Total current financial liabilities 10,44,590.00
Other current liabilities 53,340.00
1 Other current liabilities 53,340.00
Total of other current liabilities 53,340.00
Provisions, current 31,540.00
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 11,29,470.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 12,43,590.00
Total equity and liabilites 44,37,030.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Global Generics 5,00,280.00 9,58,050.00
2 Pharmaceutical Services and Active Ingredients 76,270.00 1,50,760.00
3 Others 1,430.00 2,500.00
Total Segment Revenue 5,77,980.00 11,11,310.00
Less: Inter segment revenue 20,720.00 40,390.00
Revenue from operations 5,57,260.00 10,70,920.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Global Generics 1,03,900.00 1,60,320.00
2 Pharmaceutical Services and Active Ingredients (16,590.00) (33,750.00)
3 Others 960.00 1,560.00
Total Profit before tax 88,270.00 1,28,130.00
i. Finance cost 7,700.00 15,010.00
ii. Other Unallocable Expenditure net off Unallocable income (9,560.00) (26,710.00)
Profit before tax 90,130.00 1,39,830.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Global Generics 0.00 0.00
2 Pharmaceutical Services and Active Ingredients 0.00 0.00
3 Others 0.00 0.00
Total Segment Asset 0.00 0.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 0.00 0.00
4 Segment Liabilities
Segment Liabilities
1 Global Generics 0.00 0.00
2 Pharmaceutical Services and Active Ingredients 0.00 0.00
3 Others 0.00 0.00
Total Segment Liabilities 0.00 0.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 0.00 0.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss (2,100.00) 11,150.00
Total Amount of items that will be reclassified to profit and loss (2,100.00) 11,150.00
4 Income tax relating to items that will be reclassified to profit or loss (520.00) 2,810.00
5 Total Other comprehensive income (1,580.00) 8,340.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,39,830.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 15,010.00
Adjustments for decrease (increase) in inventories (66,040.00)
Adjustments for decrease (increase) in trade receivables, current (87,990.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (41,730.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 44,760.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 65,140.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss (1,000.00)
Adjustments for provisions, current 40,910.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (13,040.00)
Adjustments for dividend income 0.00
Adjustments for interest income 40,990.00
Adjustments for share-based payments 1,850.00
Adjustments for fair value losses (gains) (8,970.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 640.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (91,450.00)
Net cash flows from (used in) operations 48,380.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 40,800.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 7,580.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 2,21,780.00
Other cash payments to acquire equity or debt instruments of other entities 1,55,950.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 6,330.00
Purchase of property, plant and equipment 51,380.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 10,770.00
Purchase of intangible assets 7,750.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 4,980.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 58,660.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities 77,480.00
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 3,160.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 3,100.00
Repayments of borrowings 0.00
Payments of lease liabilities 2,500.00
Dividends paid 66,640.00
Interest paid 18,320.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (81,200.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 3,860.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (410.00)
Net increase (decrease) in cash and cash equivalents 3,450.00
Cash and cash equivalents cash flow statement at beginning of period 33,750.00
Cash and cash equivalents cash flow statement at end of period 37,200.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited
Declaration of unmodified opinion or statement on impact of audit qualification
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Dr. Reddy's Laboratories Limited K Satish Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 168.00 Approved 84.00 0.00 0.00
2 Dr. Reddy's Laboratories Limited K Samrajyam Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 24.20 Approved 12.10 0.00 0.00
3 Dr. Reddy's Laboratories Limited K Deepti Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 21.00 Approved 10.50 0.00 0.00
4 Dr. Reddy's Laboratories Limited G Anuradha Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 136.50 Approved 68.30 0.00 0.00
5 Dr. Reddy's Laboratories Limited G.V.Sanjana Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 31.50 Approved 15.80 0.00 0.00
6 Dr. Reddy's Laboratories Limited G.Mallika Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 26.30 Approved 13.20 0.00 0.00
7 Dr. Reddy's Laboratories Limited Green Park Hospitality Services Private Limited Entities with joint control or significant influence over entity Purchase of goods or services 6,270.00 Approved 3,000.00 0.00 0.00
8 Dr. Reddy's Laboratories Limited Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Purchase of goods or services 500.00 Approved 267.00 0.00 0.00
9 Dr. Reddy's Laboratories Limited Stamlo Industries Limited Entities with joint control or significant influence over entity Purchase of goods or services 150.00 Approved 62.00 0.00 0.00
10 Dr. Reddy's Laboratories Limited Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Purchase of goods or services 1,800.00 Approved 820.00 0.00 0.00
11 Dr. Reddy's Laboratories Limited Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Any other transaction Lab Facility 270.00 Approved 0.00 0.00 0.00
12 Dr. Reddy's Laboratories Limited Indian School of Business Entities with joint control or significant influence over entity Any other transaction Campus placement, training and development services 25.00 Approved 6.00 0.00 0.00
13 Dr. Reddy's Laboratories Limited Indus Projects Private Limited Entities with joint control or significant influence over entity Any other transaction Civil Contract works 2,701.00 Approved 420.00 0.00 0.00
14 Dr. Reddy's Laboratories Limited Zenfold Sustainable Technologies Private Limited Entities with joint control or significant influence over entity Any other transaction Purchase 1,987.00 Approved 600.00 0.00 0.00
15 Dr. Reddy's Laboratories Limited Zenfold Sustainable Technologies Private Limited Entities with joint control or significant influence over entity Any other transaction Sale 90.00 Approved 38.00 0.00 0.00
16 Dr. Reddy's Laboratories Limited Dr.Reddy’s Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 8,000.00 Approved 3,200.00 0.00 0.00
17 Dr. Reddy's Laboratories Limited Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Any other transaction Contributions for social development 450.00 Approved 0.00 0.00 0.00
18 Dr. Reddy's Laboratories Limited Nayanta Education Entities with joint control or significant influence over entity Any other transaction Contributions for social development 1,000.00 Approved 1,000.00 0.00 0.00
19 Dr. Reddy's Laboratories Limited PAGE Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 1,000.00 Approved 250.00 0.00 0.00
20 Dr. Reddy's Laboratories Limited Wildlife Trust of India Entities with joint control or significant influence over entity Any other transaction Contributions for social development 100.00 Approved 66.00 0.00 0.00
21 Dr. Reddy's Laboratories Limited NICE Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 250.00 Approved 97.00 0.00 0.00
22 Dr. Reddy's Laboratories Limited Naandi Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 100.00 Approved 40.00 0.00 0.00
23 Dr. Reddy's Laboratories Limited Narsingh Swain Memorial Trust (Aakar Asha hospital) Entities with joint control or significant influence over entity Any other transaction Contributions for social development 112.00 Approved 50.00 0.00 0.00
24 Dr. Reddy's Laboratories Limited WWF- India (World Wide Fund for Nature ) Entities with joint control or significant influence over entity Any other transaction Contributions for social development 120.00 Approved 0.00 0.00 0.00
25 Aurigene Pharmaceutical Services Limited, India Dr.Reddy’s Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 200.00 Approved 15.00 0.00 0.00
26 Aurigene Pharmaceutical Services Limited, India Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Purchase of goods or services 30.00 Approved 0.00 0.00 0.00
27 Aurigene Pharmaceutical Services Limited, India Green Park Hospitality Services Private Limited Entities with joint control or significant influence over entity Any other transaction Canteen services 180.00 Approved 91.00 0.00 0.00
28 Aurigene Pharmaceutical Services Limited, India Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Any other transaction Hotel expenses 20.00 Approved 8.00 0.00 0.00
29 Aurigene Pharmaceutical Services Limited, India Stamlo Industries Limited Entities with joint control or significant influence over entity Any other transaction Hotel expenses 20.00 Approved 7.00 0.00 0.00
30 Aurigene Oncology Limited Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Any other transaction Hotel expenses 10.00 Approved 0.00 0.00 0.00
31 Aurigene Oncology Limited Stamlo Industries Limited Entities with joint control or significant influence over entity Any other transaction Hotel expenses 10.00 Approved 0.00 0.00 0.00
32 Dr. Reddy’s Formulations Limited Green Park Hospitality Services Private Limited Entities with joint control or significant influence over entity Any other transaction Canteen services 100.00 Approved 37.00 0.00 0.00
33 Dr. Reddy’s Formulations Limited Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Any other transaction Hotel expenses 5.00 Approved 0.00 0.00 0.00
34 Dr. Reddy’s Formulations Limited Stamlo Industries Limited Entities with joint control or significant influence over entity Any other transaction Hotel expenses 2.00 Approved 0.00 0.00 0.00
35 Dr. Reddy's Nestle and Health Science Limited Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Any other transaction Hotel expenses 30.00 Approved 12.00 0.00 0.00
36 Dr. Reddy's Nestle and Health Science Limited Stamlo Industries Limited Entities with joint control or significant influence over entity Any other transaction Hotel expenses 10.00 Approved 0.00 0.00 0.00
37 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Sale of goods or services 2,000.00 Approved 672.00 0.00 0.00
38 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Purchase of goods or services 20,000.00 Approved 4,878.00 0.00 0.00
39 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Any other transaction Manpower services 6,000.00 Approved 557.00 0.00 0.00
40 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Any other transaction Marketing and promotional services 1,100.00 Approved 0.00 0.00 0.00
41 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Any other transaction Royalty income 1,400.00 Approved 509.00 0.00 0.00
42 Dr. Reddy's Laboratories Limited Kunshan Rotam Reddy Pharmaceuticals Joint ventures where entity is venturer Sale of goods or services 2,000.00 Approved 701.00 0.00 0.00
43 Dr. Reddy's Laboratories Limited Kunshan Rotam Reddy Medical Company Joint ventures where entity is venturer Sale of goods or services 1,000.00 Approved 0.00 0.00 0.00
44 Dr. Reddy's Laboratories Limited DRES Energy Private Limited Joint ventures where entity is venturer Purchase of goods or services 1,500.00 Approved 570.00 0.00 0.00
45 Dr. Reddy's Laboratories Limited O2 Renewable Energy IX Private Limited Joint ventures where entity is venturer Purchase of goods or services 6,000.00 Approved 2,131.00 0.00 0.00
46 Dr. Reddy's Laboratories Limited Dr. Reddy’s ESOS Trust ESOS Trust Any other transaction Cashless Charges 25.00 Approved 3.00 0.00 0.00
47 Dr. Reddy's Laboratories Limited DRES Energy Private Limited Joint ventures where entity is venturer Any other transaction Rent Income 100.00 Approved 3.00 0.00 0.00
48 Dr. Reddy’s Bio-sciences Limited, India DRES Energy Private Limited Joint ventures where entity is venturer Any other transaction Rental income- Land 6.00 Approved 2.00 0.00 0.00
49 Aurigene Oncology Limited Clean Renewable Energy KK 2A Pvt Ltd Entities with joint control or significant influence over entity Purchase of goods or services 720.00 Approved 160.00 0.00 0.00
50 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Sale of goods or services 6,00,000.00 Approved 2,20,000.00 0.00 0.00
51 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Russia Holding-Subsidiary Sale of goods or services 3,00,000.00 Approved 1,49,100.00 0.00 0.00
52 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Sale of goods or services 60,000.00 Approved 28,300.00 0.00 0.00
53 Dr. Reddy's Laboratories Limited Dr. Reddy’s (Thailand) Limited, Thailand Holding-Subsidiary Sale of goods or services 5,400.00 Approved 1,300.00 0.00 0.00
54 Dr. Reddy's Laboratories Limited Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Holding-Subsidiary Sale of goods or services 20,000.00 Approved (1,600.00) 0.00 0.00
55 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (UK) Limited, UK Holding-Subsidiary Sale of goods or services 40,000.00 Approved 19,400.00 0.00 0.00
56 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Ukraine Holding-Subsidiary Sale of goods or services 20,000.00 Approved 6,100.00 0.00 0.00
57 Dr. Reddy's Laboratories Limited betapharmArzneimittel GmbH, Germany Holding-Subsidiary Sale of goods or services 50,300.00 Approved 26,000.00 0.00 0.00
58 Dr. Reddy's Laboratories Limited Reddy Pharma SAS, France Holding-Subsidiary Sale of goods or services 8,000.00 Approved 800.00 0.00 0.00
59 Dr. Reddy's Laboratories Limited Dr Reddy’s Laboratories LLP, Kazakhstan Holding-Subsidiary Sale of goods or services 36,000.00 Approved 17,600.00 0.00 0.00
60 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa Holding-Subsidiary Sale of goods or services 25,000.00 Approved 7,300.00 0.00 0.00
61 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories SAS, Colombia Holding-Subsidiary Sale of goods or services 14,000.00 Approved 10,900.00 0.00 0.00
62 Dr. Reddy's Laboratories Limited Reddy Pharma Iberia SAU, Spain Holding-Subsidiary Sale of goods or services 14,500.00 Approved 4,400.00 0.00 0.00
63 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Sale of goods or services 21,500.00 Approved 3,800.00 0.00 0.00
64 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Canada, Inc., Canada Holding-Subsidiary Sale of goods or services 1,20,000.00 Approved 13,800.00 0.00 0.00
65 Dr. Reddy's Laboratories Limited Dr. Reddy’s Srl Holding-Subsidiary Sale of goods or services 20,000.00 Approved 4,800.00 0.00 0.00
66 Dr. Reddy's Laboratories Limited Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil Holding-Subsidiary Sale of goods or services 40,000.00 Approved 11,600.00 0.00 0.00
67 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia Holding-Subsidiary Sale of goods or services 5,000.00 Approved 3,900.00 0.00 0.00
68 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Malaysia Sdn. Bhd., Malaysia Holding-Subsidiary Sale of goods or services 9,100.00 Approved 3,400.00 0.00 0.00
69 Dr. Reddy's Laboratories Limited Dr. Reddy’s New Zealand Limited, New Zealand Holding-Subsidiary Sale of goods or services 1,500.00 Approved 200.00 0.00 0.00
70 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Chile SPA., Chile Holding-Subsidiary Sale of goods or services 5,000.00 Approved 1,600.00 0.00 0.00
71 Dr. Reddy's Laboratories Limited Aurigene Oncology Limited, India Holding-Subsidiary Sale of goods or services 200.00 Approved 0.00 0.00 0.00
72 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (EU) Limited, UK Holding-Subsidiary Sale of goods or services 9,300.00 Approved 800.00 0.00 0.00
73 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Philippines Inc. Holding-Subsidiary Sale of goods or services 2,700.00 Approved 300.00 0.00 0.00
74 Dr. Reddy's Laboratories Limited Dr.Reddy’s laboratories Jamaica Limited Holding-Subsidiary Sale of goods or services 10,000.00 Approved 3,600.00 0.00 0.00
75 Dr. Reddy's Laboratories Limited Dr. Reddy’s Formulations Limited Holding-Subsidiary Sale of goods or services 1,700.00 Approved 0.00 0.00 0.00
76 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Russia Holding-Subsidiary Purchase of goods or services 55,000.00 Approved 25,800.00 0.00 0.00
77 Dr. Reddy's Laboratories Limited Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Holding-Subsidiary Purchase of goods or services 20,000.00 Approved 5,400.00 0.00 0.00
78 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Ukraine Holding-Subsidiary Purchase of goods or services 10,000.00 Approved 4,000.00 0.00 0.00
79 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Purchase of goods or services 7,500.00 Approved 3,500.00 0.00 0.00
80 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (EU) Limited, UK Holding-Subsidiary Purchase of goods or services 8,500.00 Approved 4,000.00 0.00 0.00
81 Dr. Reddy's Laboratories Limited Dr Reddy’s Laboratories LLP, Kazakhstan Holding-Subsidiary Purchase of goods or services 7,500.00 Approved 4,000.00 0.00 0.00
82 Dr. Reddy's Laboratories Limited Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited, China Holding-Subsidiary Purchase of goods or services 4,000.00 Approved 2,100.00 0.00 0.00
83 Dr. Reddy's Laboratories Limited Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil Holding-Subsidiary Purchase of goods or services 2,000.00 Approved 300.00 0.00 0.00
84 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Purchase of goods or services 3,000.00 Approved 600.00 0.00 0.00
85 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Japan KK, Japan Holding-Subsidiary Purchase of goods or services 1,000.00 Approved 500.00 0.00 0.00
86 Dr. Reddy's Laboratories Limited Aurigene Oncology Limited, India Holding-Subsidiary Purchase of goods or services 5,000.00 Approved 200.00 0.00 0.00
87 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Taiwan Limited, Taiwan Holding-Subsidiary Purchase of goods or services 700.00 Approved 200.00 0.00 0.00
88 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (UK) Limited, UK Holding-Subsidiary Purchase of goods or services 100.00 Approved 0.00 0.00 0.00
89 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Vietnam Company Limited Holding-Subsidiary Purchase of goods or services 18,100.00 Approved 0.00 0.00 0.00
90 Dr. Reddy's Laboratories Limited Idea2enterprises (India) Private Limited Holding-Subsidiary Any other transaction Rental Expense 637.00 Approved 189.00 0.00 0.00
91 Dr. Reddy's Laboratories Limited DRL Impex Limited Holding-Subsidiary Any other transaction Rental Expense 39.00 Approved 20.00 0.00 0.00
92 Dr. Reddy's Laboratories Limited Cheminor Investments Limited Holding-Subsidiary Any other transaction Rental Expense 19.00 Approved 9.00 0.00 0.00
93 Dr. Reddy's Laboratories Limited Dr. Reddy’s Bio-sciences Limited, India Holding-Subsidiary Any other transaction Rental Expense 92.00 Approved 45.00 0.00 0.00
94 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Any other transaction Rental income 1,000.00 Approved 458.00 0.00 0.00
95 Dr. Reddy's Laboratories Limited Dr. Reddy’s Formulations Limited Holding-Subsidiary Any other transaction Rental income 500.00 Approved 123.00 0.00 0.00
96 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Any other transaction Interest Income 12,000.00 Approved 4,710.00 0.00 0.00
97 Dr. Reddy's Laboratories Limited Aurigene Oncology Limited, India Holding-Subsidiary Any other transaction Interest Income 1,000.00 Approved 408.00 0.00 0.00
98 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Sale of goods or services 2,50,000.00 Approved 1,11,600.00 0.00 0.00
99 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Romania SRL Holding-Subsidiary Sale of goods or services 35,000.00 Approved 11,200.00 0.00 0.00
100 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Sale of goods or services 6,000.00 Approved 0.00 0.00 0.00
101 Dr. Reddy’s Laboratories Romania SRL Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Sale of goods or services 17,000.00 Approved 6,800.00 0.00 0.00
102 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories LLC, Russia Holding-Subsidiary Sale of goods or services 6,000.00 Approved 1,700.00 0.00 0.00
103 betapharmArzneimittel GmbH, Germany Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Sale of goods or services 4,400.00 Approved 1,200.00 0.00 0.00
104 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories Canada, Inc., Canada Holding-Subsidiary Sale of goods or services 10,000.00 Approved 5,500.00 0.00 0.00
105 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Sale of goods or services 500.00 Approved 100.00 0.00 0.00
106 Aurigene Pharmaceutical Services Limited, India Aurigene Oncology Limited, India Holding-Subsidiary Sale of goods or services 1,000.00 Approved 0.00 0.00 0.00
107 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Kazakhstan LLP Holding-Subsidiary Sale of goods or services 700.00 Approved 400.00 0.00 0.00
108 Dr. Reddy’s Laboratories (EU) Limited, UK Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Sale of goods or services 22,000.00 Approved 5,300.00 0.00 0.00
109 betapharmArzneimittel GmbH, Germany Reddy Pharma Iberia SA Holding-Subsidiary Sale of goods or services 500.00 Approved 0.00 0.00 0.00
110 Aurigene Discovery Technologies (Malaysia) SDN BHD Aurigene Oncology Limited, India Holding-Subsidiary Sale of goods or services 1,000.00 Approved 300.00 0.00 0.00
111 Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia Dr. Reddy’s New Zealand Limited, New Zealand Holding-Subsidiary Sale of goods or services 200.00 Approved 0.00 0.00 0.00
112 Dr. Reddy’s Laboratories (UK) Limited, UK Reddy Pharma Iberia SA Holding-Subsidiary Sale of goods or services 100.00 Approved 0.00 0.00 0.00
113 Dr. Reddy’s Laboratories LLC, Russia Dr. Reddy’s Laboratories Kazakhstan LLP Holding-Subsidiary Sale of goods or services 100.00 Approved 0.00 0.00 0.00
114 Dr. Reddy’s Laboratories (Canada) Inc. Dr. Reddy’s Laboratories (UK) Limited, UK Holding-Subsidiary Sale of goods or services 5,500.00 Approved 2,200.00 0.00 0.00
115 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Canada, Inc., Canada Holding-Subsidiary Sale of goods or services 20,400.00 Approved 9,600.00 0.00 0.00
116 Dr. Reddy’s Laboratories (EU) Limited, UK Dr. Reddy’s Laboratories (UK) Limited, UK Holding-Subsidiary Sale of goods or services 700.00 Approved 300.00 0.00 0.00
117 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories LLC, Ukraine Holding-Subsidiary Sale of goods or services 1,000.00 Approved 400.00 0.00 0.00
118 Reddy Pharma SAS, France Reddy Pharma Iberia SA Holding-Subsidiary Sale of goods or services 500.00 Approved 0.00 0.00 0.00
119 Dr. Reddy’s Laboratories SAS, Colombia Dr. Reddy's Laboratories Chile SPA., Chile Holding-Subsidiary Sale of goods or services 2,000.00 Approved 0.00 0.00 0.00
120 Dr. Reddy’s Srl Reddy Pharma Iberia SA Holding-Subsidiary Sale of goods or services 1,500.00 Approved 0.00 0.00 0.00
121 Dr. Reddy’s Laboratories SA, Switzerland betapharmArzneimittel GmbH, Germany Holding-Subsidiary Sale of goods or services 3,600.00 Approved 1,200.00 0.00 0.00
122 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa Holding-Subsidiary Sale of goods or services 2,200.00 Approved 1,300.00 0.00 0.00
123 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s New Zealand Limited, New Zealand Holding-Subsidiary Sale of goods or services 9,500.00 Approved 4,000.00 0.00 0.00
124 Dr. Reddy’s Laboratories (UK) Limited, UK Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia Holding-Subsidiary Sale of goods or services 27,000.00 Approved 16,900.00 0.00 0.00
125 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (UK) Limited Holding-Subsidiary Sale of goods or services 34,000.00 Approved 20,600.00 0.00 0.00
126 Dr. Reddy’s Farmaceutica Do Brasil Ltda. Dr. Reddy's Laboratories Chile SPA., Chile Holding-Subsidiary Sale of goods or services 3,000.00 Approved 0.00 0.00 0.00
127 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s (Thailand) Limited, Thailand Holding-Subsidiary Sale of goods or services 900.00 Approved 0.00 0.00 0.00
128 Dr. Reddy’s Laboratories SA, Switzerland Dr Reddy's Denmark ApS Holding-Subsidiary Sale of goods or services 52,900.00 Approved 29,200.00 0.00 0.00
129 Dr.Reddy’s Netherlands BV betapharmArzneimittel GmbH, Germany Holding-Subsidiary Sale of goods or services 10,600.00 Approved 6,400.00 0.00 0.00
130 Reddy Pharma Iberia SAU, Spain Dr. Reddy’s Srl Holding-Subsidiary Sale of goods or services 800.00 Approved 200.00 0.00 0.00
131 Dr. Reddy’s Laboratories (UK) Limited, UK Reddy Pharma Iberia SA Holding-Subsidiary Sale of goods or services 100.00 Approved 0.00 0.00 0.00
132 Dr. Reddy’s Laboratories (UK) Limited, UK Dr. Reddy’s Srl Holding-Subsidiary Sale of goods or services 600.00 Approved 100.00 0.00 0.00
133 Dr. Reddy’s Laboratories SA, Switzerland Reddy Pharma SAS, France Holding-Subsidiary Sale of goods or services 500.00 Approved 500.00 0.00 0.00
134 Dr. Reddy’s Laboratories SA, Switzerland Dr.Reddy’s Netherlands BV Holding-Subsidiary Sale of goods or services 40,700.00 Approved 28,900.00 0.00 0.00
135 Dr.Reddy’s Netherlands BV Reddy Pharma SAS, France Holding-Subsidiary Sale of goods or services 9,000.00 Approved 0.00 0.00 0.00
136 Dr. Reddy’s Laboratories SA, Switzerland Reddy Pharma Iberia SAU, Spain Holding-Subsidiary Sale of goods or services 700.00 Approved 100.00 0.00 0.00
137 betapharmArzneimittel GmbH, Germany Dr. Reddy’s Srl Holding-Subsidiary Sale of goods or services 3,000.00 Approved 800.00 0.00 0.00
138 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Sale of goods or services 500.00 Approved 0.00 0.00 0.00
139 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Dr. Reddy’s Laboratories (EU) Limited, UK Holding-Subsidiary Sale of goods or services 400.00 Approved 100.00 0.00 0.00
140 Dr. Reddy’s Laboratories (UK) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Sale of goods or services 1,000.00 Approved 0.00 0.00 0.00
141 Reddy Pharma SAS, France betapharmArzneimittel GmbH, Germany Holding-Subsidiary Sale of goods or services 200.00 Approved 0.00 0.00 0.00
142 Reddy Pharma Iberia SAU, Spain betapharmArzneimittel GmbH, Germany Holding-Subsidiary Sale of goods or services 100.00 Approved 0.00 0.00 0.00
143 Dr. Reddy’s Laboratories Taiwan Limited, Taiwan Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Sale of goods or services 1,000.00 Approved 0.00 0.00 0.00
144 Dr. Reddy’s Laboratories SAS, Colombia Dr. Reddy's Laboratories Chile SPA., Chile Holding-Subsidiary Sale of goods or services 2,000.00 Approved 0.00 0.00 0.00
145 Dr.Reddy’s Netherlands BV Dr. Reddy’s Laboratories Romania SRL Holding-Subsidiary Sale of goods or services 150.00 Approved 0.00 0.00 0.00
146 Dr. Reddy’s Laboratories Inc., USA Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Sale of goods or services 2,500.00 Approved 840.00 0.00 0.00
147 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (Australia) Pty. Limited Holding-Subsidiary Interest received 800.00 Approved 417.00 0.00 0.00
148 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Chile SPA., Chile Holding-Subsidiary Interest received 100.00 Approved 19.00 0.00 0.00
149 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories SAS, Colombia Holding-Subsidiary Interest received 39.00 Approved 0.00 0.00 0.00
150 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy's Laboratories Philippines Inc. Holding-Subsidiary Interest received 100.00 Approved 22.00 0.00 0.00
151 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy`s Research and Development B.V. Holding-Subsidiary Interest received 100.00 Approved 16.00 0.00 0.00
152 Dr. Reddy’s Laboratories SA, Switzerland Reddy Pharma Iberia SA Holding-Subsidiary Interest received 100.00 Approved 52.00 0.00 0.00
153 Dr. Reddy’s Laboratories SA, Switzerland betapharmArzneimittel GmbH, Germany Holding-Subsidiary Interest received 100.00 Approved 0.00 0.00 0.00
154 Dr. Reddy’s Laboratories SA, Switzerland North Star Sweden AB Holding-Subsidiary Interest received 100.00 Approved 1.00 0.00 0.00
155 Dr. Reddy’s Laboratories SA, Switzerland Dr Reddy's Denmark ApS Holding-Subsidiary Interest received 100.00 Approved 50.00 0.00 0.00
156 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (EU) Limited, UK Holding-Subsidiary Interest received 200.00 Approved 89.00 0.00 0.00
157 Lacock Holdings Limited Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 100.00 Approved 2.00 0.00 0.00
158 Dr. Reddy’s Srl Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 200.00 Approved 110.00 0.00 0.00
159 Reddy Pharma SAS, France Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 100.00 Approved 51.00 0.00 0.00
160 Northstar Switzerland SARL Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 3,800.00 Approved 1,908.00 0.00 0.00
161 North Star OpCo Limited Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 400.00 Approved 109.00 0.00 0.00
162 Reddy Netherlands B.V. Dr. Reddy`s Research and Development B.V. (formerly Octoplus BV) Holding-Subsidiary Interest received 100.00 Approved 54.00 0.00 0.00
163 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Canada, Inc., Canada Holding-Subsidiary Interest received 400.00 Approved 178.00 0.00 0.00
164 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s New Zealand Limited, New Zealand Holding-Subsidiary Interest received 200.00 Approved 68.00 0.00 0.00
165 Dr. Reddy’s Laboratories SA, Switzerland Northstar Switzerland SARL Holding-Subsidiary Interest received 100.00 Approved 4.00 0.00 0.00
166 Dr. Reddy’s Laboratories (EU) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 100.00 Approved 29.00 0.00 0.00
167 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy's Venezuela, C.A. Holding-Subsidiary Interest received 400.00 Approved 0.00 0.00 0.00
168 Dr. Reddy’s Laboratories SA, Switzerland Reddy Netherlands B.V. Holding-Subsidiary Interest received 300.00 Approved 0.00 0.00 0.00
169 Dr. Reddy’s Laboratories SA, Switzerland Northstar OpCo Holding-Subsidiary Interest received 100.00 Approved 0.00 0.00 0.00
170 betapharmArzneimittel GmbH, Germany Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 2,600.00 Approved 1,463.00 0.00 0.00
171 Dr. Reddy’s Laboratories (UK) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 2,200.00 Approved 1,007.00 0.00 0.00
172 Dr Reddy's Denmark ApS Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 200.00 Approved 7.00 0.00 0.00
173 Aurigene Oncology Limited, India Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Interest received 600.00 Approved 0.00 0.00 0.00
174 betapharmArzneimittel GmbH, Germany Nimbus Health GmbH Holding-Subsidiary Interest received 80.00 Approved 0.00 0.00 0.00
175 Reddy Holding GmbH Nimbus Health GmbH Holding-Subsidiary Interest received 200.00 Approved 122.00 0.00 0.00
176 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Interest received 8,000.00 Approved 500.00 0.00 0.00
177 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Any other transaction Other Income 3,500.00 Approved 1,224.00 0.00 0.00
178 Aurigene Oncology Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Any other transaction Rental Income 2,500.00 Approved 245.00 0.00 0.00
179 Dr. Reddy’s Laboratories (EU) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Any other transaction Other Income 300.00 Approved 109.00 0.00 0.00
180 Dr. Reddy’s Laboratories Inc., USA Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Any other transaction Other Income 4,000.00 Approved 834.00 0.00 0.00
181 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories Canada, Inc., Canada Holding-Subsidiary Any other transaction Other Income 300.00 Approved 0.00 0.00 0.00
182 Dr. Reddy’s Laboratories SA, Switzerland Northstar Switzerland SARL Holding-Subsidiary Any other transaction Other Income 20,000.00 Approved 7.00 0.00 0.00
183 beta Institut gemeinnutzige GmbH betapharm Arzneimittel GmbH Holding-Subsidiary Any other transaction Other Income 700.00 Approved 211.00 0.00 0.00
184 betapharm Arzneimittel GmbH Reddy Holding GmbH Holding-Subsidiary Any other transaction Other Income 400.00 Approved 64.00 0.00 0.00
185 Northstar OpCo Dr. Reddy’s Laboratories (UK) Limited, UK Holding-Subsidiary Any other transaction Other Income 1,300.00 Approved 423.00 0.00 0.00
186 Dr. Reddy’s Laboratories SA, Switzerland Northstar OpCo Holding-Subsidiary Any other transaction Other Income 1,500.00 Approved 0.00 0.00 0.00
187 Dr. Reddy’s Laboratories Inc., USA Aurigene Oncology Limited Holding-Subsidiary Any other transaction Other Income 630.00 Approved 153.00 0.00 0.00
188 Dr. Reddy’s Laboratories SA, Switzerland Reddy Netherlands B.V. Holding-Subsidiary Any other transaction Other Income 1,000.00 Approved 0.00 0.00 0.00
189 Dr. Reddy’s Laboratories Romania SRL Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Any other transaction Other Income 13,000.00 Approved 0.00 0.00 0.00
190 Northstar Switzerland SARL Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Any other transaction Other Income 10,000.00 Approved 4,535.00 0.00 0.00
191 Reddy Netherlands B.V. Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Any other transaction Other Income 1,600.00 Approved 948.00 0.00 0.00
192 Dr Reddy's Denmark ApS Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Any other transaction Other Income 600.00 Approved (115.00) 0.00 0.00
193 Dr. Reddy’s Laboratories Canada, Inc., Canada Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Any other transaction Other Income 200.00 Approved 0.00 0.00 0.00
194 Dr. Reddy’s Laboratories (UK) Limited, UK Northstar OpCo Holding-Subsidiary Any other transaction Other Income 1,500.00 Approved 0.00 0.00 0.00
195 Dr Reddy's Denmark ApS Reddy Netherlands B.V. Holding-Subsidiary Any other transaction Other Income 600.00 Approved 300.00 0.00 0.00
196 Dr. Reddy's Laboratories Limited G V Prasad Key management personnel of entity or parent Remuneration 2,030.00 Approved 134.30 0.00 0.00
197 Dr. Reddy's Laboratories Limited K Satish Reddy Key management personnel of entity or parent Remuneration 1,260.00 Approved 137.90 0.00 0.00
198 Dr. Reddy's Laboratories Limited Deepak Sapra Key management personnel of entity or parent Remuneration 799.60 Approved 333.20 0.00 0.00
199 Dr. Reddy's Laboratories Limited Mannam Venkata Narasimham Key management personnel of entity or parent Remuneration 1,088.10 Approved 453.40 0.00 0.00
200 Dr. Reddy's Laboratories Limited M V Ramana Key management personnel of entity or parent Remuneration 1,378.30 Approved 574.30 0.00 0.00
201 Dr. Reddy's Laboratories Limited Krishna Venkatesh Key management personnel of entity or parent Remuneration 632.60 Approved 263.60 0.00 0.00
202 Dr. Reddy's Laboratories Limited Milan Kalawadia Key management personnel of entity or parent Remuneration 1,456.00 Approved 606.70 0.00 0.00
203 Dr. Reddy's Laboratories Limited Sanjay Sharma Key management personnel of entity or parent Remuneration 1,133.20 Approved 472.20 0.00 0.00
204 Dr. Reddy's Laboratories Limited Erez Israeli Key management personnel of entity or parent Remuneration 3,242.80 Approved 1,351.20 0.00 0.00
205 Dr. Reddy's Laboratories Limited Patrick Aghanian Key management personnel of entity or parent Remuneration 1,728.70 Approved 720.30 0.00 0.00
206 Dr. Reddy's Laboratories Limited Sushrut Kulkarni Key management personnel of entity or parent Remuneration 600.00 Approved 250.40 0.00 0.00
207 Dr. Reddy's Laboratories Limited Kumar Randhir Singh Key management personnel of entity or parent Remuneration 204.40 Approved 85.20 0.00 0.00
208 Dr. Reddy's Laboratories Limited Bhethanabottla S Phanimitra Key management personnel of entity or parent Remuneration 589.20 Approved 245.50 0.00 0.00
209 Dr. Reddy's Laboratories Limited Akhil Ravi Relatives of Key management personnel Remuneration 396.40 Approved 165.20 0.00 0.00
210 Dr. Reddy's Laboratories Limited Vishal Reddy Relatives of Key management personnel Remuneration 0.00 Approved 0.00 0.00 0.00
211 Dr. Reddy's Laboratories Limited Shravya Reddy Kallam Relatives of Key management personnel Remuneration 34.50 Approved 14.40 0.00 0.00
212 Dr. Reddy's Laboratories Limited Madhu Sundar Munnirpallam Subramanian Key management personnel of entity or parent Remuneration 498.00 Approved 207.50 0.00 0.00
213 Dr. Reddy's Laboratories Limited Sandeep Pramod Khandelwal Key management personnel of entity or parent Remuneration 713.20 Approved 297.20 0.00 0.00
214 Dr. Reddy's Laboratories Limited Sridevi Khambhampaty Key management personnel of entity or parent Remuneration 181.90 Approved 75.80 0.00 0.00
Total value of transaction during the reporting period 9,03,782.20